Ambit Biosciences Corp. has raised $22 million, according to a June 29 filing by the Sorrento Valley-based company with the SEC.The filing states that Ambit Biosciences had sought about $30 million, leaving about $8 million to raise. The company describes itself as focused on discovery and development of cancer ddrugs from small molecule kinase inhibitors. Ambit’s president and CEO is biotech/pharma veteran Alan Lewis, who most recently was president and CEO of the Juvenile Diabetes Research Foundation. Before that, Lewis was president and CEO of Novocell, now ViaCyte, developing stem cell-based treatments for diabetes. Lewis was also CEO of Signal Pharmaceuticals, purchased in 2000 by Celgene.
